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ABSTRACT
Coronavirus disease 2019 (COVID-19) is an emerging disease caused bysevere 
acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that has been causing 
many people around the world affected. There is no approved treatment 
for COVID-19. Meanwhile, vaccine development still needs a long time 
before it becomes available to protect people from contracting COVID-19. 
Repurposing the available drugs is one of the fastest ways to get COVID-19 
treatment. Studies have been conducted to discover for COVID-19 treatment 
that results in the finding of potential medication for COVID-19. Chloroquine 
and hydroxychloroquine are some of the available medication that shows 
potential for COVID-19 treatment. Preclinical study showed that the both drugs 
are active against SARS-CoV-2 in vitro. A pilot clinical study also showed their 
efficacy in COVID-19 treatment. Many clinical trials are now being conducted to 
prove their safety and efficacy for the prevention and treatment of COVID-19. 
However, until now there are not enough data to support the use of these drugs 
in COVID-19 management. Under the pressure to treat COVID-19 patients with 
chloroquine or hydroxychloroquine, clinicians shouldnot use these drugs for 
COVID-19 without considering the available information regarding theiruse 
for COVID-19. This review summarized the evidence regarding the potential of 
chloroquine and hydroxychloroquine in COVID-19 management.
ABSTRAK
Coronavirus disease 2019 (COVID-19) adalah penyakit akibat infeksi severe acute 
respiratory syndrome coronavirus-2 (SARS-CoV-2) yang telah menyebabkan 
banyak orang di seluruh dunia terkena dampaknya. Sampai saat ini belum ada 
obat yang terbukti secara ilmiah untuk COVID-19. Sementara itu pengembangan 
vaksin masih membutuhkan waktu yang lama untuk melindungi orang dari 
tertular COVID-19. Penggunaan obat yang telah beredar menjadi salah satu 
cara tercepat dalam mendapatkan obat untuk COVID-19. Penelitian sebelum 
ini berhasil menemukan beberapa obat yang potensial untuk COVID-19. 
Klorokuin dan hidroksi klorokuin merupakan salah satu diantara obat yang 
potensial. Penelitian preklinik menunjukkan kedua obat ini aktif secara in 
vitro terhadap SARS-CoV-2. Penelitian klinik skala pilot juga menunjukkan 
kemanjurannya dalam pengobatan COVID-19. Saat ini sedang dilakukan uji 
klinik untuk membuktikan keamanan dan kemanjuran kedua obat ini untuk 
pencegahan dan pengobatan COVID-19. Namun demikian, belum ada data 
yang cukup untuk mendukung penggunaan kedua obat untuk pengobatan 
COVID-19. Di bawah tekanan untuk mengobati pasien COVID-19 dengan 
klorokuin atau hidroksiklorokuin, dokter tidak boleh menggunakan kedua 
obat iniuntuk COVID-19 tanpa mempertimbangkan informasi yang tersedia 
tentang penggunaannya untuk COVID-19. Ulasan ini akan merangkum bukti 
mengenai klorokuin dan hidroksi klorokuin dalam pengobatan COVID-19.
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INTRODUCTION
Chloroquine   and   hydroxychloroquine 
have been used for malaria prevention 
and treatment for a long time ago. 
Chloroquine is synthesized based on 
the structure of the active compound 
found in the bark of the Cinchona tree 
or fever tree.1 Hydroxychloroquine 
was synthesized almost 20 years after 
chloroquine was synthesized. It is 
known as a safer drug compared to 
chloroquine even though they have an 
almost similar structure except for the 
hydroxyl (OH) moiety in one terminal 
of hydroxychloroquine structure.2 Both 
drugs belong to 4-aminoquinoline groups 
which are among the first drugs used to 
treat malaria. However, the intensive 
use of these drugs caused Plasmodium 
resistance towards these drugs that lead 
to a significant drop of the use of these 
drugs as anti-malaria.3 Besides its well-
known antimalarial action, chloroquine 
and hydroxychloroquine are also being 
used for rheumatoid arthritis (RA), 
systematic lupus erythematosus (SLE) 
and other inflammatory diseases.4
During coronavirus disease-19 
(COVID-19) pandemic in whichthe 
decisive treatment guidelines are not yet 
available, repurposing some currently 
available medications becomes one of 
the fastest ways to provide treatment for 
the patient. Chloroquine and its derivate 
hydroxychloroquine are proven to have 
activity against severe acute respiratory 
syndrome coronavirus-2 (SARS-CoV-2)
in vitro.5 The result of the in vitro study 
becomes the foundation of the use of 
chloroquine and hydroxychloroquine 
for COVID-19. Readily available, long-
term experience of usage and low 
cost support the use of chloroquine 
and hydroxychloroquine in COVID-19. 
However, consideration to use 
chloroquine and hydroxychloroquine 
for COVID-19 should take into account 
the safety of the medication and the 
fact that there is no valid data about its 
efficacy in COVID-19.
This review was made to summarize 
the current state of understanding of 
chloroquine and hydroxychloroquine 
use for COVID-19. Articles were searched 
using several keywords namely 
chloroquine, hydroxychloroquine, SARS-
CoV-2, and COVID-19. The related articles 
were reviewed and summarized in this 
manuscript. Until this review was made 
on 27 May 2020, there were only a few 
published research data related to the use 
of chloroquine and hydroxychloroquine 
as COVID-19.
DISCUSSION
Chloroquine and hydroxychloroquine 
as antimalarial
In the blood, Plasmodium enters 
erythrocytes andgrows by consuming 
hemoglobin and processing them in the 
food vacuole. In the food vacuole of the 
Plasmodium, hemoglobin is degraded 
into peptide and heme. Free heme 
accumulation as a result of hemoglobin 
digestion in the food vacuole can 
cause membrane lysis that can lead 
to the generation of reactive oxygen 
species (ROS) and other destructive 
consequences. Therefore, the heme 
is detoxified in the Plasmodium food 
vacuole by changing it into hemozoin, a 
large insoluble crystal containing heme.6
Chloroquine and 
hydroxychloroquine is a weak base. 
Chloroquine can be found in un-
protonated, mono-protonated, and di-
protonated forms in the physiological 
condition. The un-protonated forms 
of chloroquine can easily enter the 
cell membrane and food vacuole 
membrane in which chloroquine will 
be accumulated.7 The accumulation 
of chloroquine into the food vacuole 
is selective which suggested being 
the result of chloroquine protonation 
due to the low pH of the food vacuole, 
active uptake by parasite transporter, 
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and chloroquine binding to a specific 
receptor in the food vacuole.8 In the 
food vacuole, chloroquine interferes 
with the heme detoxification process 
which results in heme accumulation 
and subsequently toxic consequences 
willhappen.9 Their ability to accumulate 
in the lysosome seems to be crucial for 
most of their activity including their 
immunomodulatory and antiviral 
activity.
Chloroquine and hydroxychloroquine 
as immunomodulator
Chloroquine and 
hydroxychloroquine are also used to 
treat autoimmune diseases such as RA 
and SLE. Several in vitro studies reveal 
its immunomodulatory activity. It has 
been known that chloroquine and 
hydroxychloroquine are accumulated 
in lysosome inside the lymphocytes 
and interfere with lysosomal and 
autophagosome activity in the 
lymphocyte. As a result, the lymphocyte 
function is inhibited which results in 
chloroquine and hydroxychloroquine 
immunomodulatory effect.10 Lysosomes 
and autophagosome is known to have 
a role in processing and presenting 
antigen which then promoting 
immune activation.11-12 As a weak base, 
chloroquine and hydroxychloroquine 
increase the pH in the lysosomes 
and autophagosomes which causes 
inhibition of their maturation. Inhibition 
of lysosomes and autophagosomes 
function results in inhibition of immune 
activation.2,13 Besides, chloroquine and 
hydroxychloroquine also suggested to be 
able to prevent Toll-like receptor (TLR) 
activation through their ability to increase 
endosomal pH.14 In vitro study also shows 
chloroquine and hydroxychloroquine 
ability to inhibit cytokines production 
by mononuclear cells.15 The ability of 
chloroquine and hydroxychloroquine 
to modulate the immune system might 
be important in COVID-19 in which 
over-activity of immune response 
is suggested to worsen the disease. 
FIGURE 1 shows the chloroquine and 
hydroxychloroquine mechanism of 
action as an immunomodulator.
FIGURE 1. Chloroquine and hydroxychloroquine mechanism of action as 
immunomodulator.
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Chloroquine and hydroxychloroquine 
as antiviral
The study regarding the antiviral 
activity of chloroquine was first 
reported decades ago. Since then, many 
studies have been performed to explore 
its potential as antiviral.16 Study in 
Vero cells infected with Chikungunya 
virus (CHIKV) showed that chloroquine 
could reduce virus yield and viral RNA 
copy number.17 However, a clinical 
trial in 2006 failed to prove the efficacy 
of chloroquine in chikungunya virus 
infection. Compare to the placebo-
treated group, the chloroquine treated 
group showed the same mean duration 
of febrile arthralgia and rate of viremia 
decrease in CHIKV infected patients.18 
Chloroquine also has in vitro activity 
against Ebola virus.19 In contrast, a study 
in guinea pig suggested that chloroquine 
did not protect the animal against the 
Ebola disease.19 Based on chloroquine 
activity to inhibit H1N1 and H3N2 
Influenza A virus (IAV) strain replication 
in vitro, clinical trial have been done 
in Singapore to evaluate chloroquine 
efficacy to prevent IAV infection.20-21 
Several in vitro studies also suggested 
chloroquine and hydroxychloroquine 
antiviral effect against other viruses 
such as human immunodeficiency 
virus (HIV), hepatitis C virus (HCV),and 
dengue virus (DENV).22-24 Chloroquine 
and hydroxychloroquine also have been 
studied in coronavirus, in which SARS-
CoV-2 belongs to. In vitro studies also 
have been done to evaluate chloroquine 
activity against coronaviruses, SARS-
Cov and MERS-CoV.25-26 The broad 
spectrum of chloroquine and its analog 
hydroxychloroquine as antiviral make 
them attractive to repurpose it for 
treatment of viral infection including 
the current coronavirus infection, SARS-
CoV-2, the culprit that cause COVID-19.
There are several explanations of 
chloroquine and hydroxychloroquine 
mechanism of action as an agent 
for the prevention and treatment 
of viral infection. Chloroquine and 
hydroxychloroquine can interrupt 
the virus replication by intervening 
endosome-mediated viral entry. 
Some viruses infect the target cells by 
endocytosis. In the lysosome of the cells, 
the virus is exposed to low pH and action 
of several enzymes that will degrade the 
virus and liberate the infectious nucleic 
acid and sometimes enzymes necessary 
for viral replication.27 Chloroquine is also 
known to inhibit budding of enveloped 
virus particles since chloroquine could 
increase pH which will interrupt 
pH-dependent post-translational 
modification of the new virus in the 
endoplasmic and trans-Golgi network.28 
In vitro chloroquine administration 
before SARS-CoV infection in Vero 
cells causes angiotensin-converting 
enzyme 2 (ACE2) terminal glycosylation 
impairment that results in reduced 
binding affinities between ACE2 and 
SARS-CoV spike protein and inhibits 
the initiation of SARS-CoV infection.29 
FIGURE 2 shows the antiviral mechanism 
of chloroquine and hydroxychloroquine. 
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FIGURE 2. Chloroquineand hydroxychloroquinemechanism of action as 
antiviral.
Chloroquine and hydroxychloroquine 
for COVID-19 
Chloroquine and 
hydroxychloroquine show in vitro 
activity against SARS-CoV-2. Chloroquine 
administration before SARS-CoV-2 
inoculation to Vero6 cells shows a greater 
inhibition of viral replication than 
simultaneous or later administration 
of chloroquine.30 This might important 
to its potential for SARs-CoV-2 infection 
prevention. Meanwhile, another in vitro 
study shows that hydroxychloroquine 
is more effective than chloroquine in 
terms of inhibiting SARS-COV-2. The 
effective concentration of 50% (EC50) 
of hydroxychloroquine is 0.72µM. 
Meanwhile, the EC50 of chloroquine is 
5.47µM.31
Some studies report that chloroquine 
phosphate is superior in controlling 
exacerbation of pneumonia, improving 
lung imaging findings, triggering negative 
virus conversion, and shortening illness 
duration in COVID-19 patient but no data 
was included in the report.32 In contrast, 
a new study in Brazilian Amazon 
showed that hospitalized COVID-19 
patients receiving chloroquine are failed 
to show substantial viral clearance by 
day four even when it co-administered 
with azithromycin and or oseltamivir.33 
However, several countries have 
already included chloroquine and 
hydroxychloroquine in their COVID-19 
treatment guideline i.e China, Korea, 
Belgia, Italy, etc.34-37 Clinical trials have 
been recorded at https://clinicaltrials.
gov to evaluate the safety and efficacy 
of chloroquine as an agent for the 
prevention and treatment of COVID-19.38
A study by Gautret et al.39 in France 
have shown hydroxychloroquine 
efficacy as COVID-19 treatment. The 
study involved 36 COVID-19 patients 
with asymptomatic disease (six people), 
upper respiratory tract infection (22 
people), and lower respiratory tract 
infection (eight people). The presence of 
the virus on the patient’s nasal swab at 
day sixpost-inclusion of the study was 
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examined. The result showed that the 
administration of hydroxychloroquine 
decreased viral carriage on the 6th day 
after obtaining the drug.39 However, 
there are some limitations of the clinical 
study including the small number of 
samples andthe comparator group is not 
homogeneous.
Safety of chloroquine and 
hydroxychloroquine
The most common adverse effect of 
chloroquine and hydroxychloroquineis 
a gastrointestinal disturbance that 
includes nausea, and vomiting.40 Several 
studies also have reported the occurrence 
of chloroquine or hydroxychloroquine-
mediated cardiotoxicity that commonly 
occurs as rhythm disorders, i.e. prolonged 
QT interval on the electrocardiogram.41 
In addition, chloroquine and 
hydroxychloroquine are related to 
retinopathy. The retinal damage related 
to chloroquine and hydroxychloroquine 
is caused bythe disturbance of 
photoreceptor outer segments lysosomal 
degradation by the retinal pigment 
epithelium that leads to an increase in 
lipofuscin in retinal pigment epithelial 
cells and photoreceptor degradation.42 
There are several  risk  factors  for the 
development of retinopathy during 
hydroxychloroquine treatment. 
These factors are a drug dose of 
more than 5 mg/kg body weight/day, 
hydroxychloroquine treatment for 
more than 5 years, cumulative dose 
above 600–1,000g, chronic kidney 
disease, and hydroxychloroquine co-
treatment with tamoxifen for more 
than six months. Hydroxychloroquine 
with its N-hydroxyethyl side chain that 
makes it more soluble than chloroquine 
is considered to be less toxic than 
chloroquine.42 Therefore, it might be 
preferable to focus research effort on 
hydroxychloroquine than chloroquine.
Chloroquine and hydroxychloroquine 
dosing consideration in COVID-19 
treatment 
Chloroquine phosphate 250 mg 
is equivalent to 150 mg base and 
hydroxychloroquine 200 mg is equivalent 
to 155 mg base.43-44 Chloroquine dose 
for Malaria acute attack is started with 
one g and followed by 500 mg after 
6-8 hours and 500 mg single dose for 
two days. The total chloroquine dose 
for the whole treatment course is 
2.5 g.43 Hydroxychloroquine dose for 
uncomplicated malaria is 800 mg and 
followed by 400 mg after six hours, 24 
hours, and 48 hours of the initial dose. 
The total hydroxychloroquine dose for 
the whole treatment course is two g.44 
Meanwhile, hydroxychloroquine dose 
for SLE and RA is 200-400 mg/dayand 400-
600 mg/day respectively as a single dose 
or in two divided doses. The chloroquine 
and hydroxychloroquine dose for 
malaria, RA, and SLE are well tolerated. 
However, higher doses and longer 
duration of treatment with chloroquine 
and hydroxychloroquine are often 
related to side effects i.e cardiac rhythm 
disturbance and retinopathy
The dose of chloroquine and 
hydroxychloroquine in COVID-19 
management is not conclusive yet. 
Based on a pharmacokinetic simulation 
study, the recommended dosage of 
hydroxychloroquine sulfate is 400 
mg twice a day on day one, followed 
by 200 mg twice a day on days 2-5. 
Total hydroxychloroquine for the 
whole treatment duration is 2.4 g.31 
The guideline from Belgia for mild to 
moderate COVID-19 also recommends 
the same dose with those calculated 
in the pharmacokinetic simulation 
study.36 Meanwhile, COVID-19 treatment 
guidelines from China recommend a 
higher dose of chloroquine phosphate 
than the dose for malaria. They 
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recommend chloroquine phosphate 
500 mg/dose twice daily until day seven 
for adults with bodyweight over 50 kg 
and 500 mg/dose twice daily for day 
one followed by 500 mg/dose/day until 
day seven for adults with bodyweight 
less than 50 kg. The total dose for the 
whole treatment is ranging from 4-7 
g.34 COVID-19 treatment Guideline from 
Korea recommends hydroxychloroquine 
instead of chloroquine since chloroquine 
is  not  available in Korea. The 
recommends hydroxychloroquine dose 
for COVID-19 is 400 mg/day for 7-10 days. 
The total dose is 2.8-4 g.35 This showed 
that some guidelines recommend 
Chloroquine and hydroxychloroquine 
dose higher than those used for malaria 
treatment. 
Chloroquine and 
hydroxychloroquine are known to 
havelarge volume distribution and long 
half-life (32-50 days).32 Therefore, the 
duration of treatment should not more 
than fivedays to avoid the accumulation 
of the drugs in the plasma and tissue 
which is related to an increased risk 
of toxicity.36 Clinical trial in Brazilian 
Amazone that compared high dose (600 
mg twice a day for 10 days) versus low 
dose (450 mg twice a day on day one and 
once daily for four days) of chloroquine 
in hospitalized COVID-19 patient showed 
that more QTc interval prolongation and 
lethality in high dose chloroquine treated 
group. In this study, total Chloroquine 
administration during treatment 
duration is 12 g that the total dose is 
higher than the total recommended dose 
of chloroquine and hydroxychloroquine 
for malaria. The study finding suggests 
that high dose of chloroquine should 
not be used for severe or critically ill 
COVID-19 patients especially in patients 
who also receive azithromycin and 
oseltamivir.33 Multinational registry 
analysis involved 96032 patients from 6 
different continents showed that the use 
of chloroquine and hydroxychloroquine 
with or without macrolide for COVID-19 
increased the risk of ventricular 
arrhythmia in hospitalized patients. 
However, the dose of chloroquine and 
hydroxychloroquine used was not 
mentioned in this study.45 Since the study 
used data from many countries, the dose 
of chloroquine and hydroxychloroquine 
must be varied. Subgroup analysis or 
dose-response analysis should be done 
to differentiate the effect of chloroquine 
and hydroxychloroquine various 
doses. Nevertheless, this showed that 
chloroquine and hydroxychloroquine 
should not be used as routine drugs for 
COVID-19 without careful consideration 
of their risk and benefit until firm 
evidence of their use in COVID-19 is 
confirmed.
CONCLUSION 
No solid clinical trial data available 
currently to support the use of these 
drugs for COVID-19 patients. Randomized 
controlled clinical trial is urgently needed 
to evaluate the efficacy and safety of 
chloroquine and hydroxychloroquine 
for COVID-19 prevention and treatment. 
It might also important to focus 
research on hydroxychloroquine 
rather than chloroquine by considering 
hydroxychloroquine safer profile than 
chloroquine.
ACKNOWLEDGEMENT
I would like to express my special 
thanks of gratitude to my colleague 
in Department of Pharmacology and 
Therapy Faculty of Medicine, Public 
Health and Nursing Universitas Gadjah 
Mada for the support and guidance to 
write this review.
REFERENCES
1. Permin H, Norn S, Kruse E, Kruse 
PR. On the history of Cinchona bark 
in the treatment of Malaria. Dan 
Medicinhist Arbog 2016; 44:9-30.
89
J Med Sci, Volume 52, Number 3 (SI), 2020, Juli: 82-91
2. Schrezenmeier E, Dorner 
T. Mechanism of action 
ofhydroxychloroquine and 
chloroquine: implications for 
rheumatology. Nat Rev Rheumatol 
2020; 16(3):155-66.
https://doi.org/10.1038/s41584-020-0372-x
3. Al-Bari MA. Chloroquine analogues 
in drug discovery: New directions 
of uses, mechanisms of actions and 
toxic manifestations from malaria to 
multifarious diseases. J Antimicrob 
Chemother 2015; 70:1608–21.
https://doi.org/10.1093/jac/dkv018
4. Rainsfors KD, Parke AL, Clifford-
Rashotte M, Kean WF. Therapy 
and pharmacological properties 
of hydroxychloroquine and 
chloroquine in treatment of systemic 
lupus erythematosus, rheumatoid 
arthritis and related diseases. 
Inflammopharmacology 2015; 
23(5):231-69.
https://doi.org/10.1007/s10787-015-0239-y
5. Liu J, Cao R, Xu M, Wang X, Zhang H, 
Hu H, et al. Hydroxychloroquine, a 
less toxic derivate of chloroquine, is 
as effective in inhibiting SARS-CoV-2 
infection in vitro. Cell Discov 2020; 
6:16.
https://doi.org/10.1038/s41421-020-0156-0
6. Ridley RG. Malaria: dissecting 
chloroquine resistance. Curr Biol 
1998; 8(10):R346-9.
h t t p s : / / d o i . o r g / 1 0 . 1 0 1 6 / s 0 9 6 0 -
9822(98)70218-0
7. Homewood CA, Warhurst DC, Peters 
W, Baggaley VC. Lysosomes, pH and the 
anti-malarial action of chloroquine. 
Nature 1972; 235(5332):50-2.
https://doi.org/10.1038/235050a0
8. Yayon A, Cabantchik ZI, Ginsburg 
H. Identification of the acidic 
compartment of Plasmodium 
falciparum-infected human 
erythrocytes as the target of the 
antimalarial drug chloroquine. 
EMBO J 1984; 3(11):2695-700.
9. Sullivan DJ Jr, Matile H, Ridley RG, 
Goldberg DE. A common mechanism 
for blockade of heme polymerization 
by antimalarial quinolines. J Biol 
Chem 1998; 273(47):31103–7.
https://doi.org/0.1074/jbc.273.47.31103
10. Circu M, Cardelli J, Barr MP, O’Byrne 
K, Mills G, El-Osta H. Modulating 
lysosomal function through lysosome 
membrane permeabilization or 
autophagy suppression restores 
sensitivity to cisplatin in refractory 
non-small-cell lung cancer cells. PLoS 
One 2017; 12(9):e0184922.
https:/ /doi.org/10.1371/journal.
pone.0184922
11. Ballabio A, Bonifacino JS. Lysosomes 
as dynamic regulators of cell and 
organismal homeostasis. Nat Rev Mol 
Cell Biol 2019; 21(2):101-18.
https://doi.org/10.1038/s41580-019-0185-4
12. Ghislat G, Lawrence T. Autophagy in 
dendritic cells. Cell Mol. Immunol 
2018; 15:944-52.
https://doi.org/10.1038/cmi.2018.2
13. Rebecca VW, Nicastri MC, Fennelly 
C, Chude CI, Barber-Rotenberg JS, 
Ronghe A, et al. PPT1 promotes tumor 
growth and is the molecular target of 
chloroquine derivatives in cancer. 
Cancer Discov 2019; 9(2):220-9.
https://doi.org/10.1158/2159-8290.CD-
18-0706
14. Ewald SE, Lee BL, Lau L, Wickliffe 
KE, Shi GP, Chapman HA, et al. The 
ectodomain of Toll-like receptor 9 
is cleaved to generate a functional 
receptor. Nature 2008; 456(7222):658-
62.
https://doi.org/10.1038/nature07405
15. van den Borne BE, Dijkmans BA, de 
Rooij HH, le Cessie S, Verweij CL. 
Chloroquine and hydroxychloroquine 
equally affect tumor necrosis factor-
alpha, interleukin 6, and interferon-
gamma production by peripheral 
blood mononuclear cells. J Rheumatol 
1997; 24(1):55-60.
16. D’Alessandro S, Scaccabarozzi 
D, Signorini L, Perego F, Ilboudo 
DP, Ferrante P, et al. Theuse 
of antimalarial drugs against 
90
Nugrahaningsih DAA, et al., Chloroquine and...
viralinfection. Microorganism 2020; 
8(1):E85.
h t t p s : / / d o i . o r g / 1 0 . 3 3 9 0 /
microorganisms8010085
17. Khan M, Santhosh SR, Tiwari M, 
Lakshmana Rao PV, Parida M. 
Assessment of in vitro prophylactic 
and therapeutic efficacy of 
chloroquine against Chikungunya 
virus in Vero cells. J Med Virol 2010; 
82(5):817-24.
https://doi.org/10.1002/jmv.21663
18. De Lamballerie X, Boisson V, Reynier 
JC, Enault S, Charrel RN, Flahault A, 
et al. On chikungunya acute infection 
and chloroquine treatment. Vector 
Borne Zoonotic Dis 2008; 8(6):837-9.
https://doi.org/10.1089/vbz.2008.0049
19. Dowall SD, Bosworth A, Watson R, 
Bewley K, Taylor I, Rayner E, et al. 
Chloroquine inhibited Ebola virus 
replication in vitro but failed to 
protect against infection and disease 
in the in vivo guinea pig model. J Gen 
Virol 2015; 96:3484-92.
https://doi.org/10.1089/vbz.2008.0049
20. Ooi EE, Chew JS, Loh JP, Chua RC. In 
vitro inhibition of human influenza 
A virus replication by chloroquine. 
Virol J 2006; 3:39.
https://doi.org/10.1186/1743-422X-3-39
21. Paton NI, Lee L, Xu Y, Ooi EE, Cheung 
YB, Archuleta S, et al. Chloroquine for 
influenza prevention: A randomised, 
double-blind, placebocontrolled trial. 
Lancet Infect Dis 2011; 11:677-83.
h t t p s : / / d o i . o r g / 1 0 . 1 0 1 6 / s 1 4 7 3 -
3099(11)70065-2
22. Jacobson JM, Bosinger SE, Kang M, 
Belaunzaran-Zamudio P, Matining 
RM, Wilson CC, et al. The effect of 
chloroquine on immune activation 
and interferon signatures associated 
with HIV-1. AIDS Res Hum Retrovir 
2016; 32(7):636-47.
https://doi.org/10.1089/AID.2015.0336
23. Blanchard E, Belouzard S, Goueslain 
L, Wakita T, Dubuisson J, Wychowski 
C, et al. Hepatitis C virus entry depends 
on clathrin-mediated endocytosis. J 
Virol 2006; 80:6964-72.
https://doi.org/10.1128/JVI.00024-06
24. Borges MC, Castro LA, Fonseca BA. 
Chloroquine use improves dengue-
related symptoms. Mem Inst Oswaldo 
Cruz 2013; 108(5):596-9.
h t t p s : / / d o i . o r g / 1 0 . 1 5 9 0 / s 0 0 7 4 -
02762013000500010
25. Keyaerts E, Vijgen L, Maes P, Neyts 
J, Van Ranst M. In vitro inhibition of 
severe acute respiratory syndrome 
coronavirus by chloroquine. 
Biochem Biophys Res Commun 2004; 
323(1):264-8.
https://doi.org/10.1016/j.bbrc.2004.08.085
26. Dyall J, Coleman CM, Hart BJ, 
Venkataraman T, Holbrook MR, 
Kindrachuk J, et al. Repurposing 
of clinically developed drugs for 
treatment of Middle East respiratory 
syndrome coronavirus infection. 
Antimicrob Agents Chemother 2014; 
58(8):4885-93.
https://doi.org/10.1128/AAC.03036-14
27. Cassell S, Edwards J, Brown DT. Effects 
of lysosomotropic weak bases on 
infection of BHK-21 cells by Sindbis 
virus. J Virol 1984; 52(3):857-64.
28. Savarino A, Gennero L, Sperber K, 
Boelaert JR. The anti-HIV-1 activity 
of chloroquine. J Clin Virol 2001; 
20(3):131-5.
h t t p s : / / d o i . o r g / 1 0 . 1 0 1 6 / s 1 3 8 6 -
6532(00)00139-6
29. Vincent MJ, Bergeron E, Benjannet 
S, Erickson BR, Rollin PE, Ksiazek 
TG. Chloroquine is a potent inhibitor 
of SARS coronavirus infection and 
spread. Virol J 2005; 2:69.
https://doi.org/ 10.1186/1743-422X-2-69
30. Wang M, Cao R, Zhang L, Yang X, 
Liu J, Xu M, et al. Remdesivir and 
chloroquine effectively inhibit the 
recently emerged novel coronavirus 
(2019-nCoV) in vitro. Cell Res 2020; 
30(3):269-71.
https://doi.org/10.1038/s41422-020-0282-0
31. Liu J, Cao R, Xu M, Wang X, Zhang H, 
Hu H, et al. Hydroxychloroquine, a 
less toxic derivate of chloroquine, is 
91
J Med Sci, Volume 52, Number 3 (SI), 2020, Juli: 82-91
as effective in inhibiting SARS-CoV-2 
infection in vitro. Cell Discov 2020; 6:16.
https://doi.org/10.1038/s41421-020-0156-0
32. Gao J, Tian Z, Yang X. Breakthrough: 
chloroquine phosphate has shown 
apparent efficacy in treatment of 
COVID-19 associated pneumonia in 
clinical studies. Biosci Trends 2020; 
14(1):72-3.
https://doi.org/10.5582/bst.2020.01047
33. Borba MGS, Val FFA, Sampaio VS, 
Alexandre MAA, Melo GC, Brito 
M, et al. Effect of high vs low doses 
of chloroquine diphosphate as 
adjunctive therapy for patients 
hospitalized with severe acute 
respiratory syndrome coronavirus 2 
(SARS-CoV-2) infection: arandomized 
clinical trial. JAMA Netw Open 2020; 
3(4):e208857. 
34. China National Health Comission. 
Chinese clinical guidance for 
COVID-19 pneumonia diagnosis 
and treatment, 7th ed. March 4th, 
2020. Available from:http://kjfy.
meetingchina.org/msite/news/show/
cn/3337.html
35. Korea Biomedical Review. Physicians 
work out treatment guidelines for 
coronavirus. Available from: https://
w w w. ko r e a b i o m e d . c o m / n e w s /
articleView.html?idxno=7428. 
36. Interim clinical guideline for adult 
with suspected or conformed 
COVID-19 in Belgium. Available 
from: https://epidemio.wiv-isp.be/
ID/Documents/Covid19/COVID19_
InterimGuidelines_Treatment_ENG. 
37. Italian Society of Infectious and 
Tropical Diseases. Handbook for the 
care of people with disease-COVI 19. 
2.0 ed., 2020.
38. Clinical trial. gov. Available from: 
https:/ /clinicaltrials.gov/ct2/re-
sults?cond=COVID19&term=chloro-
quine&cntry=&state=&city=&dist.Ac-
cessed on April 30th, 2020.
39. Gautret P, Lagier JC, Parola P, 
Hoang VT, Meddeb L, Mailhe M, 
et al.Hydroxychloroquine and 
azithromycin as a treatment of 
COVID-19: results of an open-label 
non-randomized clinical trial. Int J 
Antimicrob Agents 2020; 105949. 
h t t p s : / / d o i . o r g / 1 0 . 1 0 1 6 / j .
ijantimicag.2020.105949
40. Srinivasa A, Tosounidou S, 
Gordon C. Increased incidence 
of gastrointestinal side effects in 
patients taking hydroxychloroquine: 
a brand-related issue? J Rheumatol 
2017; 44(3):398.
https://doi.org/10.3899/jrheum.161063
41. Chatre C, Roubille F, Vernhet 
H, Jorgensen C, Pers YM. 
Cardiac complications 
attributed to chloroquine and 
hydroxychloroquine: a systematic 
reviewof the literature. Drug Saf 
2018; 41(10):919-31.
https://doi.org/10.1007/s40264-018-0689-4
42. Jorge A, Ung C, Young LH, Melles 
RB, Choi HK. Hydroxychloroquine 
retinopathy implications of research 
advances for rheumatology care. Nat 
Rev Rheumatol 2018; 14(12):693-703. 
https://doi.org/10.1038/s41584-018-0111-8
43. Rx List. Aralendrug description. 
Available from: https://www.rxlist.
com/aralen-drug.htm. Accessed on 
April 30th, 2020.
44. Rx List. Plaquenil drug description. 
Available from: https://www.rxlist.
com/ plaquenil-drug.htm. Accessed 
on April 30th, 2020.
45. Mehra MR, Desai SS, Ruschitzka 
F, Patel AN. Hydroxychloroquine 
or chloroquine with or without a 
macrolide for treatment of COVID-19: 
a multinational registry analysis. 
Lancet 2020; S0140-6736(20):31180-6.
ht tps : / /do i .org /10 .1016 /S0140-
6736(20)31180-6
